Citation Impact
Citing Papers
Risk Factors for Venous Thromboembolism
2003 Standout
Polyphosphate modulates blood coagulation and fibrinolysis
2006
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Defensin Promotes the Binding of Lipoprotein(a) to Vascular Matrix
1999
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
Extracellular Matrix Reorganization During Wound Healing and Its Impact on Abnormal Scarring
2013 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Chemerin Activation by Serine Proteases of the Coagulation, Fibrinolytic, and Inflammatory Cascades
2005
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Reduced activity of TAFI (thrombin‐activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia
2000
Overture for growth hormone: Requiem for interleukin-6?*
2007
Sepsis biomarkers: a review
2010 Standout
Acute Coagulopathy of Trauma: Hypoperfusion Induces Systemic Anticoagulation and Hyperfibrinolysis
2008
The study of social cognition with neuroimaging methods as a means to explore future directions of deficit evaluation in schizophrenia?
2010
Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome
2003
Haemostatic materials for wound healing applications
2021 Standout
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) at the Interface between Coagulation and Fibrinolysis
2003
Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection
2008 Standout
The Role of Plasminogen-Plasmin System in Cancer
2009
New Antithrombotic Drugs
2008
Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
2010 StandoutNobel
TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction
2004 StandoutNobel
Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis
2001
The metabolic syndrome
2010 Standout
New Antithrombotic Drugs
2012
Thrombin activatable fibrinolysis inhibitor (TAFI)—How does thrombin regulate fibrinolysis?
2006
Thrombin‐activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system
2003
The Inflammatory Response to Cardiopulmonary Bypass: Part 1—Mechanisms of Pathogenesis
2008
TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation
2011
The Coagulopathy of Trauma: A Review of Mechanisms
2008
Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients
2008
Automatic amygdala response to facial expression in schizophrenia: initial hyperresponsivity followed by hyporesponsivity
2013
Complement: a key system for immune surveillance and homeostasis
2010 Standout
Antifibrinolytic Therapy and Perioperative Considerations
2017
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
2006 Standout
The metabolic syndrome
2005 Standout
Extracellular matrix structure
2015 Standout
Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor
2000
The neurochemistry of music
2013 Standout
Development of a chitosan-based wound dressing with improved hemostatic and antimicrobial properties
2008 Standout
High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis
2000
Prevention of Venous Thromboembolism
2004 Standout
Inhibition of Plasminogen Activation by Lipoprotein(a)
2003
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Neutrophils, from Marrow to Microbes
2010 Standout
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)
2001
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines
2013
Endogenous thrombin potential is higher during the luteal phase than during the follicular phase of a normal menstrual cycle
2013 StandoutNobel
Effects of human soluble thrombomodulin on experimental glomerulonephritis
2002 StandoutNobel
Extracellular histones are major mediators of death in sepsis
2009 Standout
Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside
2003
Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays
2004
Hemostatic Risk Factors for Atherothrombotic Disease: An Epidemiologic View
2001
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin
2001
Effect of Anticoagulants in Colorimetric Assay for Basic Carboxypeptidases
2002 StandoutNobel
Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development
2007 StandoutNobel
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe
2002
A Novel Approach to Arterial Thrombolysis
1999
The Common Neural Basis of Autobiographical Memory, Prospection, Navigation, Theory of Mind, and the Default Mode: A Quantitative Meta-analysis
2008 Standout
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial
2011 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway
2000
The Dynamics of Thrombin Formation
2003
Thrombin Interacts with Thrombomodulin, Protein C, and Thrombin-activatable Fibrinolysis Inhibitor via Specific and Distinct Domains
1999
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
2000
Inactivation of C3a and C5a Octapeptides by Carboxypeptidase R and Carboxypeptidase N
2002 StandoutNobel
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by Angiography
2002
Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled
2001
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
New Fundamentals in Hemostasis
2013
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
COVID-19 and its implications for thrombosis and anticoagulation
2020 Standout
Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII
2013 StandoutNobel
An evidence‐based review of poorly differentiated thyroid cancer
2007
The Oxford Handbook of Cognitive Psychology
2013
Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface
2002 StandoutNobel
Annual Research Review: Enduring neurobiological effects of childhood abuse and neglect
2016 Standout
Rational Structure-Based Design of a Novel Carboxypeptidase R Inhibitor
2002 StandoutNobel
Improving Students’ Learning With Effective Learning Techniques
2013 Standout
Development of a Genotype 325–Specific proCPU/TAFI ELISA
2003
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 Standout
Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors
2000
Hematological findings and complications of COVID ‐19
2020 Standout
Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme
2002
Nanobodies: Natural Single-Domain Antibodies
2013 Standout
Molecular Cloning and Partial Characterization of Rat Procarboxypeptidase R and Carboxypeptidase N
2000 StandoutNobel
Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency
2006
Insulin Resistance Is Associated with Increased Circulating Level of Thrombin-Activatable Fibrinolysis Inhibitor in Type 2 Diabetic Patients
2002
Modulation of Procarboxypeptidase R (ProCPR) Activation by Complementary Peptides to Thrombomodulin
2003 StandoutNobel
Works of John B. Walker being referenced
Stabilization Versus Inhibition of TAFIa by Competitive Inhibitors in Vitro
2003
The Molecular Weights, Mass Distribution, Chain Composition, and Structure of Soluble Fibrin Degradation Products Released from a Fibrin Clot Perfused with Plasmin
1999
A Kinetic Analysis of the Tissue Plasminogen Activator and DSPAα1 Cofactor Activities of Untreated and TAFIa-treated Soluble Fibrin Degradation Products of Varying Size
2001
Control of oxidative stress in small bowel: relevance to organ preservation
2006
The Intrinsic Threshold of the Fibrinolytic System Is Modulated by Basic Carboxypeptidases, but the Magnitude of the Antifibrinolytic Effect of Activated Thrombin-activable Fibrinolysis Inhibitor Is Masked by Its Instability
2004
A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor
1998
Facial Emotion Perception in Schizophrenia: A Meta-analytic Review
2009
Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis
2004
Feasibility of a music intervention protocol for patients receiving mechanical ventilatory support.
2002
Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca++-dependent complex of C-reactive protein with very-low–density lipoprotein and is a novel marker of impending disseminated intravascular coagulation
2002
The Solution Phase Interaction between Apolipoprotein(a) and Plasminogen Inhibits the Binding of Plasminogen to a Plasmin-Modified Fibrinogen Surface
1997